Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

U.N. health officials have estimated that more than 14 million children did not receive a single vaccine last year.

A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...

A federal court dismissed a journalist’s claims against Pfizer executives and a member of the former Biden Administration for ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

In light of recent revelations surrounding a new intranasal COVID-19 vaccine candidate, there is growing concern that the American public is once again being led into potentially dangerous territory ...

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.

According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...